Citigroup
AARD

Citigroup’s Aardvark Therapeutics AARD Stock Holding History

Citigroup’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151K Sell
26,299
-19,966
-43% -$93.3K ﹤0.01% 4469
2026
Q1 		$174K Buy
46,265
+45,369
+5,064% +$470K ﹤0.01% 4060
2025
Q4 		$11.8K Buy
896
+729
+437% +$9.1K ﹤0.01% 5013
2025
Q3 		$2.22K Sell
167
-1,795
-91% -$20.2K ﹤0.01% 5460
2025
Q2 		$26.5K Buy
+1,962
New +$20.2K ﹤0.01% 5013

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Citigroup's AARD Position: Q2 2026 in Review

Citigroup reduced its Aardvark Therapeutics (AARD) stake by 43% in Q2 2026, selling an estimated $93.3K and leaving 26,299 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #4469.

Citigroup first reported a position in AARD in Q2 2025 and has held it in 5 quarters since. The position peaked at $174K in Q1 2026. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Citigroup held 26,299 shares of Aardvark Therapeutics worth $151K as of Q2 2026.
  • Citigroup sold 19,966 Aardvark Therapeutics shares in Q2 2026, an estimated $93.3K.
  • Aardvark Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4469 holding.
  • Citigroup first reported a position in Aardvark Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Citigroup's Aardvark Therapeutics position peaked at $174K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.